Stock Analysis
Praxis Precision Medicines, Inc. (PRAX) Stock Analysis
Praxis Precision Medicines, Inc. (PRAX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Praxis Precision Medicines, Inc. (PRAX) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 72/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
PRAX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $328.13 |
| AIQ Score | 57/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $9.57B |
| P/E Ratio (TTM) | -25.6 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$3.23 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.58 |
| Volume | 352.89K |
| 52-week range | $160.11-$392.70 |
| RSI 14 | 61.44 |
| 50-Day SMA | $289.90 |
| 200-Day SMA | $314.58 |
| Analyst Price Target | $660.33 |
| Next Earnings | Feb 18, 2027 |
PRAXPraxis Precision Medicines, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum48
- Value—
- Quality72
- Risk resilience47
- Sentiment—
PRAX Stock Analysis Summary
Praxis Precision Medicines, Inc. (PRAX) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 72/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, PRAX has AIQ Score of 57/100 with Quality base of 72/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.
Quality (72/100) leads while Risk resilience (47/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.04% stock move · PRAX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is PRAX Bullish or Bearish Right Now?
PRAX currently has a neutral overall setup. Quality is the strongest factor at 72/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 72/100.
- - Price is +13.19% above its 50-day SMA.
- - Analyst target implies +101.24% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 4).
- - Momentum is weak at 48/100.
- - Risk Resilience is weak at 47/100.
Current Consensus
PRAX's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 6 neutral, and 4 sell votes. PRAX's 14-day RSI is 61.44, which places the stock in a constructive momentum range. PRAX's beta is 1.58, indicating greater market sensitivity than the broad market.
What Changed in PRAX?
The largest recent change in PRAX is Quality moving down by 3.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the PRAX Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
PRAX Decision Framework
Public evidence layers, setup checks, and risk context for Praxis Precision Medicines, Inc..
Praxis Precision Medicines, Inc. (PRAX) Stock Analysis
Praxis Precision Medicines, Inc. has an AIQ Score of 57/100 in a Neutral regime. Quality is strongest at 72/100. Beta is 1.58, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | PRAX is in a Neutral AIQ regime with score 57/100. |
| Signal Conflict | The primary conflict is that quality leads at 72/100 while risk lags at 47/100. |
| Factor Evidence | Momentum 48/100 · Quality 72/100 · Risk 47/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 72/100.
Momentum is 48/100 and RSI (14) is 61.4.
PRAX is in a Neutral regime at 57/100.
Risk factor is 47/100 with beta 1.58 and annual volatility 75.11%.
Current conflict: quality leads at 72/100 while risk lags at 47/100.
PRAX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
PRAX Fundamentals
PRAX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
PRAX Technical Analysis
PRAX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
PRAX Stock Catalysts
Track PRAX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
PRAX Dividend Analysis
PRAX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
PRAX Financial Data
PRAX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
PRAX Risk Analysis
PRAX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
PRAX Stock News
PRAX stock news, market tone, recent headlines, and catalyst context.
PRAX vs Biotechnology Peers
Current peer cohort: PRAX · PTGX · PVLA · QURE · RAPP. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| PRAX Current stock | 57/100 | — | 48/100 | 47/100 | 1.13 | 75.11% | Current |
| PTGX Protagonist Therapeutics, Inc. | 73/100 | 72/100 | 70/100 | 70/100 | 1.24 | 40.11% | PRAX vs PTGX |
| PVLA Palvella Therapeutics, Inc. | 70/100 | — | 84/100 | 47/100 | 1.12 | 84.47% | PRAX vs PVLA |
| QURE uniQure N.V. | 39/100 | 38/100 | 41/100 | 31/100 | 0.39 | 132.25% | PRAX vs QURE |
| RAPP Rapport Therapeutics, Inc. Common Stock | 43/100 | 42/100 | 33/100 | 39/100 | 0.35 | 62.34% | PRAX vs RAPP |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for PRAX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching PRAX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for PRAX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
PRAX Stock FAQ
What is PRAX stock price today?
Praxis Precision Medicines, Inc.'s current stock price is $328.13. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is PRAX bullish or bearish right now?
PRAX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is PRAX's market cap?
PRAX's market cap is $9.57B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is PRAX's current P/E ratio?
PRAX's current P/E ratio is -25.6 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is PRAX's RSI?
PRAX's 14-day RSI is 61.44 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is PRAX above its 50-day and 200-day moving averages?
PRAX is 13.19% from its 50-day SMA and 4.31% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is PRAX's next earnings date?
PRAX's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does PRAX pay a dividend?
PRAX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.